BSF Enterprise Plc (LON:BSFA)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.90M -31.2% |
| Revenue (ttm) | 51.07K +112.0% |
| Net Income | -1.28M |
| EPS | -0.01 |
| Shares Out | 191.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 780,799 |
| Open | 1.0500 |
| Previous Close | 1.0000 |
| Day's Range | 0.9360 - 1.2000 |
| 52-Week Range | 0.5000 - 4.0000 |
| Beta | 3.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 24, 2026 |
About BSF Enterprise
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom. [Read more]
Financial Performance
In fiscal year 2025, BSF Enterprise's revenue was 52,840, a decrease of -8.61% compared to the previous year's 57,821. Losses were -1.11 million, -33.41% less than in 2024.
Financial StatementsNews
BSF Enterprise PLC Announces Participation in The ThinkEquity Conference
London, United Kingdom--(Newsfile Corp. - October 5, 2023) - BSF Enterprise PLC (LSE: BSFA) (OTCQB: BSFAF), a company focused on unlocking the next generation of biotechnological solutions using cell-...
BSF Enterprise PLC Provides City-MixTM Bio-Pharmaceutical Update
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- BSF Enterprise PLC ("BSF" or the "Company") (LSE: BSFA), (OTCQB: BSFAF), a company focused on unlocking the next generation of biotechnological solutions usin...